Relacorilant plus nab-paclitaxel and bevacizumab produced a 59% response rate in platinum-resistant ovarian cancer in Part A of the BELLA trial.
|Videos|January 28, 2015
Dr. DeVita Discusses the 10th Edition of Cancer: Principles and Practice of Oncology
Author(s)Vincent T. DeVita, Jr., MD
Giant of Cancer Care, Vincent T. DeVita, Jr, MD, from the Yale School of Medicine, talks about the 10th Edition of Cancer: Principles and Practice of Oncology, an internationally acclaimed book geared toward practicing oncologists.
Advertisement
Giant of Cancer Care, Vincent T. DeVita, Jr., MD, from the Yale School of Medicine, talks about the 10th Edition of Cancer: Principles and Practice of Oncology, an internationally acclaimed book geared toward practicing oncologists.
Advertisement
Related to this article
Updated ASTRO recommendations favor moderate hypofractionation for all risk groups and establish 5-fraction ultrahypofractionation as a standard option in localized prostate cancer.
Updated GOBLET cohort 4 data showed a median DOR of about 15 months with pelareorep plus atezolizumab in second-line or later anal cancer.
Firmonertinib demonstrated durable antitumor activity in patients with EGFR PACC-mutated NSCLC in a phase 1b trial.
The IMpactMF trial is being discontinued after an IDMC advised that imetelstat was unlikely to improve OS in relapsed/refractory myelofibrosis.
Sac-TMT plus pembrolizumab prolonged PFS over chemoimmunotherapy in PD-L1–negative nonsquamous lung cancer.
The FDA received a BLA for etentamig in relapsed/refractory multiple myeloma, based on response and PFS gains in the phase 3 CERVINO trial.
Judy E. Garber, MD, MPH, of the Dana Farber Cancer Institute is the recipient of the 2026 Basser Global Prize.
Advertisement
Advertisement
Trending on OncLive
1
FDA Receives BLA for Etentamig in R/R Multiple Myeloma
2
Breaking Down Key Lung Cancer Data at ESMO 2026 With Drs Santos and Halmos
3
T-DXd Gains EU Approval in Residual HER2+ Early Breast Cancer
4
Elranatamab Meets Phase 3 PFS End Point in R/R Myeloma After Anti-CD38 Therapy and Lenalidomide
5